V8Y.SI Quantum Healthcare (SES) down 50% pre-market 27 Jan 2026: downside risks and forecast
We open pre-market on 27 Jan 2026 with V8Y.SI stock trading at S$0.001, down -50.00% from the previous close as liquidity squeezes and valuation questions dominate trading. Volume is 232,700 shares versus an average of 578,100, signalling thinner-than-normal liquidity. We examine why Quantum Healthcare Limited (V8Y.SI) on the SES is among today’s top losers and what investors should watch next.
V8Y.SI stock: Price action and short-term drivers
V8Y.SI opened pre-market at S$0.001, with a day range of S$0.001–S$0.002 and a previous close of S$0.002.
Trading shows a -50.00% one-day change and 232,700 shares traded, compared with an average volume of 578,100. The immediate price move is consistent with low-float microcaps where modest sell orders can halve quoted prices.
Fundamentals and valuation for Quantum Healthcare Limited (V8Y.SI)
Quantum Healthcare’s reported market cap is S$8,014,501 and revenue-per-share TTM is 0.00161. Price-to-sales is 0.62, enterprise-value-to-sales is 1.13, and price-to-book reads -2.02, reflecting negative equity on the balance sheet.
Liquidity metrics are weak: current ratio 0.25 and working capital deficit S$8,755,000. Operating margins are negative and net income per share TTM is -0.00023, so valuation looks stressed relative to larger Healthcare peers on SES.
Technicals, liquidity and trading risk
Momentum indicators show muted signals: RSI 47.22 and ADX 18.68 suggesting no clear technical trend. Average 50-day price is S$0.00118 and 200-day is S$0.00129.
Low liquidity increases execution risk: relative volume is 0.40, and on large orders slippage can be material. We flag wide bid-ask swings and limited institutional float as primary trading risks for V8Y.SI stock.
Meyka AI grade and analyst context
Meyka AI rates V8Y.SI with a score out of 100: 64.42/100 — Grade B, SUGGESTION: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Independent signals show strain: company-level rating data dated 2026-01-26 also lists a broader platform rating of C with a recommendation of Sell, highlighting mixed signals between quantitative grading and other model outputs.
V8Y.SI stock forecast and price targets
Meyka AI’s forecast model projects S$0.01122 in one year and S$0.03107 in three years from the current S$0.001. The one-year projection implies an upside of +1,021.82% and the three-year projection implies +3,007.00% versus today’s price.
For practical planning we present a conservative near-term price target of S$0.002 and an optimistic model-based one-year target of S$0.01122. Forecasts are model-based projections and not guarantees.
Risks, catalysts and sector context
Key risks include ongoing negative profitability, low current ratio, a working capital shortfall of S$8,755,000, and limited free float that magnifies volatility.
Potential catalysts would be contract wins in the vascular devices segment, improved cash runway or equity injections. The broader Healthcare sector on SES has stronger averages—PE ~22.09 and higher liquidity—so V8Y.SI faces sector-relative performance pressure.
Final Thoughts
V8Y.SI stock is a clear pre-market top loser on 27 Jan 2026, trading at S$0.001 with a -50.00% move and thinner liquidity of 232,700 shares. Fundamentals show stress: current ratio 0.25, negative net income per share -0.00023, and a working capital gap of S$8,755,000. Meyka AI’s quantitative grade places V8Y.SI at 64.42/100 (Grade B, HOLD) while other rating signals lean more cautious. Our model projects S$0.01122 in one year (model-based upside +1,021.82%), but that forecast assumes operational recovery and improved cash flow. Given the high volatility and structural balance-sheet risks, we advise close monitoring of liquidity events, corporate updates and any funding announcements. For more details and live updates see V8Y.SI on Meyka and recent market comparisons on Investing.com. Forecasts are model projections and not guarantees; investors should weigh the high downside risk against any upside scenarios carefully.
FAQs
Why did V8Y.SI stock drop 50% pre-market?
The pre-market drop to S$0.001 reflects low liquidity, modest sell orders and structural balance-sheet stress including a working capital deficit and weak current ratio.
What is the one-year outlook for V8Y.SI stock?
Meyka AI’s forecast model projects S$0.01122 in one year from S$0.001, implying model-based upside of +1,021.82%, subject to operational recovery and funding events.
What are the key risks for Quantum Healthcare (V8Y.SI)?
Primary risks are poor liquidity, negative profitability, current ratio 0.25, working capital deficit S$8,755,000, and execution risk in a small market-cap medical device company.
How does Meyka AI rate V8Y.SI stock?
Meyka AI rates V8Y.SI with a score out of 100: 64.42/100 (Grade B, HOLD). This score factors benchmarking, sector and financial metrics and is for informational use only.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
